{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:00:35Z","timestamp":1777478435350,"version":"3.51.4"},"reference-count":30,"publisher":"Wiley","issue":"18","license":[{"start":{"date-parts":[[2007,8,14]],"date-time":"2007-08-14T00:00:00Z","timestamp":1187049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The FEBS Journal"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:p>Different inhibitors of the Ca<jats:sup>2+<\/jats:sup>\/calmodulin\u2010stimulated phosphodiesterase\u20031 family have been described and used for the examination of phosphodiesterase\u20031 in cellular, organ or animal models. However, the inhibitors described differ in potency and selectivity for the different phosphodiesterase family enzymes, and in part exhibit additional pharmacodynamic actions. In this study, we demonstrate that phosphodiesterase\u20031C is expressed in the human glioblastoma cell line A172 with regard to mRNA, protein and activity level, and that lower activities of phosphodiesterase\u20032, phosphodiesterase\u20033, phosphodiesterase\u20034 and phosphodiesterase\u20035 are also present. The identity of the phosphodiesterase\u20031C activity detected was verified by downregulation of the mRNA and protein through human phosphodiesterase\u20031C specific small interfering RNA. In addition, the measured <jats:italic>K<\/jats:italic><jats:sub>m<\/jats:sub> values (cAMP, 1.7\u2003\u00b5<jats:sc>m<\/jats:sc>; cGMP, 1.3\u2003\u00b5<jats:sc>m<\/jats:sc>) are characteristic of phosphodiesterase\u20031C. We demonstrate that treatment with the Ca<jats:sup>2+<\/jats:sup> ionophore ionomycin increases intracellular Ca<jats:sup>2+<\/jats:sup> in a concentration\u2010dependent way without affecting cell viability. Under conditions of enhanced intracellular Ca<jats:sup>2+<\/jats:sup> concentration, a rapid increase in cAMP levels caused by the adenylyl cyclase activator forskolin was abolished, indicating the involvement of Ca<jats:sup>2+<\/jats:sup>\u2010activated phosphodiesterase\u20031C. The reduction of forskolin\u2010stimulated cAMP levels was reversed by phosphodiesterase\u20031 inhibitors in a concentration\u2010dependent way. Using this cellular system, we compared the cellular potency of published phosphodiesterase\u20031 inhibitors, including 8\u2010methoxymethyl\u20103\u2010isobutyl\u20101\u2010methylxanthine, vinpocetine, SCH51866, and two established phosphodiesterase\u20031 inhibitors developed by Schering\u2010Plough (named compounds\u200331 and 30). We demonstrate that up to 10\u2003\u00b5<jats:sc>m<\/jats:sc> 8\u2010methoxymethyl\u20103\u2010isobutyl\u20101\u2010methylxanthine and vinpocetine had no effect on the reduction of forskolin\u2010stimulated cAMP levels by ionomycin, whereas the more selective and up to 10\u2003000 times more potent phosphodiesterase\u20031 inhibitors SCH51866, compound\u200331 and compound\u200330 inhibited the ionomycin\u2010induced decline of forskolin\u2010induced cAMP at nanomolar concentrations. Thus, our data indicate that SCH51866 and compounds 31 and 30 are effective phosphodiesterase\u20031 inhibitors in a cellular context, in contrast to the weakly selective and low\u2010potency phosphodiesterase inhibitors 8\u2010methoxymethyl\u20103\u2010isobutyl\u20101\u2010methylxanthine and vinpocetine. A172 cells therefore represent a suitable system in which to study the cellular effect of phosphodiesterase\u20031 inhibitors. 8\u2010Methoxymethyl\u20103\u2010isobutyl\u20101\u2010methylxanthine and vinpocetine seem not to be suitable for the study of phosphodiesterase\u20031\u2010mediated functions.<\/jats:p>","DOI":"10.1111\/j.1742-4658.2007.06001.x","type":"journal-article","created":{"date-parts":[[2007,8,16]],"date-time":"2007-08-16T22:29:00Z","timestamp":1187303340000},"page":"4812-4824","source":"Crossref","is-referenced-by-count":32,"title":["Characterization of inhibitors of phosphodiesterase\u20031C on a human cellular system"],"prefix":"10.1111","volume":"274","author":[{"given":"Torsten R.","family":"Dunkern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Hatzelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,14]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.07.003"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.22.11079"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0898-6568(97)00046-6"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.41.25699"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/hh0202.104108"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-2-17"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.1997.0544"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.32.22337"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00232-001-0120-3"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(01)00688-8"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/13.5.1248"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.300.2.559"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015196125469"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00095.2004"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408535102"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.67.659"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00190.2006"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012365408215"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1532-0456(01)00202-2"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.051086"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90168-V"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012210720-7\/50004-6"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9608467"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199612000-00018"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.2.796"},{"key":"e_1_2_8_27_2","first-page":"491","article-title":"Initiation and termination of cyclic nucleotide action","volume":"159","author":"Corbin JD","year":"1998","journal-title":"Methods Enzymol"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb17156.x"},{"key":"e_1_2_8_29_2","first-page":"249","article-title":"Inhibition of human platelet aggregation by motapizone via an increase in intracellular cAMP","volume":"20","author":"Borbe HO","year":"1986","journal-title":"Agents Actions Suppl"},{"key":"e_1_2_8_30_2","first-page":"69","article-title":"Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme","volume":"10","author":"Thompson WJ","year":"1979","journal-title":"Adv Cycl Nucleotide Res"},{"key":"e_1_2_8_31_2","first-page":"458","article-title":"Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization","volume":"264","author":"Rabe KF","year":"1993","journal-title":"Am J Physiol"}],"container-title":["The FEBS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-4658.2007.06001.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1742-4658.2007.06001.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T13:57:02Z","timestamp":1698760622000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-4658.2007.06001.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,14]]},"references-count":30,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1742-4658.2007.06001.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1742-4658.2007.06001.x","archive":["Portico"],"relation":{},"ISSN":["1742-464X","1742-4658"],"issn-type":[{"value":"1742-464X","type":"print"},{"value":"1742-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,14]]}}}